The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours
Open accessAbstract
The expression of p53 protein, epidermal growth factor receptor (EGFR), and Ki-67 nuclear antigen was examined by immunohistochemistry in biopsies of 16 types of human brain tumours, including 43 astrocytomas. P53 protein, almost certainly its mutant form, was expressed in seven of the 16, and EGFR in 11 of the 16 types of tumours. In astrocytomas both the proportion of tumours which expressed p53 or EGFR increased with grade of malignancy as did the mean Ki-67 labelling index (LI): p53-0% in grade 1, 17% in grade 2, 38% in grade 3, 65% in grade 4; EGFR-0% in grade 1, 33% in grade 2, 85% in grade 3, 95% in grade 4; mean Ki-67 L1-1.1% in grades 1 and 2, 8.3% in grade 3, and 13.4% in grade 4. Astrocytomas which expressed p53 or EGFR had a significantly higher Ki-67 LI at P less than 0.05 (11.8% and 10.7%, resp.) than those that did not (6.2% or 4.1%, resp.). Patients with astrocytomas expressing p53 or EGFR had a significantly reduced survival (P = 0.035 and P = 0.007, resp.): only 11% of the p53 + ve and 13% of the EGFR + ve patients were alive at 100 weeks following diagnosis compared to 36% of p53-ve or 60% of EGFR-ve patients. Patients with Ki-67 LI greater than 5% had a reduced survival (P less than 0.0001)--none survived beyond 86 weeks following diagnosis, whilst 63% of patients with less than 5% positive cells were still alive at 100 weeks. The univariate analysis showed that in astrocytomas expression of p53 mutants, EGFR protein, and Ki-67 greater than 5% are associated with malignant progression and poor prognosis. The multivariate analysis revealed that only tumour grade and Ki-67LI were independent prognostic factors for survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U., & Stein, H. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.4.1710 · Cited by 4,173
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Mutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K., Signer, S. H., Davidson, N., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,733
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,066
The p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Mutational hot spot in the p53 gene in human hepatocellular carcinomas
Hsu, I. C., Metcalf, R. A., Sun, T., Welsh, J. A., Wang, N. J., & Harris, C. C. (1991) · Nature · doi:10.1038/350427a0 · Cited by 1,534
Libermann, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M. D., Ullrich, A., & Schlessinger, J. (1985) · Nature · doi:10.1038/313144a0 · Cited by 1,503
Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa
Bressac, B., Kew, M., Wands, J., & Ozturk, M. (1991) · Nature · doi:10.1038/350429a0 · Cited by 1,432
RECEPTORS FOR EPIDERMAL GROWTH FACTOR AND OTHER POLYPEPTIDE MITOGENS
Carpenter, G. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004313 · Cited by 1,281
Increased expression of mutant forms of p53 oncogene in primary lung cancer
Iggo, R., Bartek, J., Lane, D., Gatter, K., Harris, A. L., & Bartek, J. (1990) · The Lancet · doi:10.1016/0140-6736(90)90801-b · Cited by 1,031
p53 mutations in colorectal cancer.
Rodrigues, N. R., Rowan, A., Smith, M. E., Kerr, I. B., Bodmer, W. F., Gannon, J. V., & Lane, D. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.19.7555 · Cited by 1,003
Wong, A. J., Bigner, S. H., Bigner, D. D., Kinzler, K. W., Hamilton, S. R., & Vogelstein, B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.19.6899 · Cited by 849
Monoclonal antibody Ki‐67: its use in histopathology
BROWN, D. C., & GATTER, K. C. (1990) · Histopathology · doi:10.1111/j.1365-2559.1990.tb00788.x · Cited by 639
P53 expression in breast cancer
Cattoretti, G., Rilke, F., Andreola, S., D'Amato, L., & Delia, D. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910410204 · Cited by 601
Sugawa, N., Ekstrand, A. J., James, C. D., & Collins, V. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.21.8602 · Cited by 594
Clonal genomic alterations in glioma malignancy stages.
Cd, J., Carlbom, E., Dumanski, J. P., Hansen, M., Nordenskjöld, M., Collins, V. P., & Cavenee, W. K. (1988) · PubMed · Cited by 512
BANKS, L., MATLASHEWSKI, G., & CRAWFORD, L. (1986) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1986.tb09919.x · Cited by 495
Rearrangement of the p53 gene in human osteogenic sarcomas.
Masuda, H., Miller, C., Koeffler, H. P., Battifora, H., & Cline, M. J. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7716 · Cited by 474
Expression of epidermal growth factor receptors in human brain tumors.
Libermann, T. A., Razon, N., Bartal, A. D., Yarden, Y., Schlessinger, J., & Soreq, H. (1984) · PubMed · Cited by 473
Menon, A. G., Anderson, K. M., Riccardi, V. M., Chung, R. Y., Whaley, J. M., Yandell, D. W., Farmer, G. E., Freiman, R. N., Lee, J. K., & Li, F. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.14.5435 · Cited by 395
Humphrey, P. A., Wong, A. J., Vogelstein, B., Zalutsky, M. R., Fuller, G. N., Archer, G. E., Friedman, H. S., Kwatra, M. M., Bigner, S. H., & Bigner, D. D. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4207 · Cited by 382
Shaulsky, G., Goldfinger, N., Ben-Ze'ev, A., & Rotter, V (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.12.6565 · Cited by 356
Nistér, M., Libermann, T. A., Betsholtz, C., Pettersson, M., Claesson, L., Heldin, C., Schlessinger, J., & Westermark, B. (1988) · PubMed · Cited by 353
Revision of the world health organization classification of brain tumors for childhood brain tumors
RORKE, L. B., Gilles, F. H., Davis, R. L., & Becker, L. E. (1985) · Cancer · Cited by 305
Mitotic recombination of chromosome 17 in astrocytomas.
James, C. D., Carlbom, E., Nordenskjold, M., Collins, V. P., & Cavenee, W. K. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.8.2858 · Cited by 279
Mechanisms of p53 loss in human sarcomas.
Mulligan, L. M., Matlashewski, G. J., Scrable, H. J., & Cavenee, W. K. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.15.5863 · Cited by 269
Stanbridge, E. J. (1990) · Annual Review of Genetics · doi:10.1146/annurev.ge.24.120190.003151 · Cited by 259
27 Chromosome abnormalities in pediatric brain tumors
(1987) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(87)90306-2 · Cited by 216
p53 transformation-related protein: Detection by monoclonal antibody in mouse and human cells
Dippold, W. G., Jay, G., DeLeo, A. B., Khoury, G., & Old, L. J. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.3.1695 · Cited by 201
Growth factors: The epidermal growth factor receptor gene and its product
Hunter, T. (1984) · Nature · doi:10.1038/311414a0 · Cited by 184
Tumor suppressor genes: the p53 and retinoblastoma sensitivity genes and gene products
Levine, A. (1990) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(90)90015-s · Cited by 173
Cytogenetics and Molecular Genetics of Malignant Gliomas and Medulloblastoma
Bigner, S. H., & Vogelstein, B. (1990) · Brain Pathology · doi:10.1111/j.1750-3639.1990.tb00633.x · Cited by 158
El-Azouzi, M., Chung, R. Y., Farmer, G. E., Martuza, R. L., Black, P. M., Rouleau, G. A., Hettlich, C., Hedley‐Whyte, E. T., Zervas, N. T., & Panagopoulos, K. P. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.18.7186 · Cited by 149
Patterns of the early, gross chromosomal changes in malignant human gliomas
Bigner, S. H., Mark, J., Mahaley, M. S., & Bigner, D. D. (2008) · Hereditas · doi:10.1111/j.1601-5223.1984.tb00455.x · Cited by 134
p53 Mutations: Gains or losses?
Michalovitz, D., Halevy, O., & Oren, M. (1991) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240450108 · Cited by 107
Raghavan, R., Steart, P. V., & Weller, R. O. (1990) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1990.tb00941.x · Cited by 92
Stoscheck, C. M., & King, L. E. (1986) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240310206 · Cited by 89
Biology of gliomas: heterogeneity, oncogenes, growth factors.
Shapiro (1986) · PubMed · Cited by 76
Reifenberger, G., Prior, R., Deckert, M., & Wechsler, W. (1989) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf00718594 · Cited by 62
Overexpression of N-ras Oncogene and Epidermal Growth Factor Receptor Gene in Human Glioblastomas
Gerosa, M. A., Talarico, D., Fognani, C., Raimondi, E., Colombatti, M., Tridente, G., Carli, L. D., & Valle, G. D. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.1.63 · Cited by 62
Increased expression of mutant forms of p53 oncogene in primary lung cancer
Unit, H. A. I. O. (1990) · Lung Cancer · doi:10.1016/0169-5002(90)90155-f · Cited by 45
Cited by
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
Nishikawa, R., Ji, X. D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., & Huang, H. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.16.7727 · Cited by 936
Glioblastoma: pathology, molecular mechanisms and markers
Aldape, K., Zadeh, G., Mansouri, S., Reifenberger, G., & von Deimling, A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1432-1 · Cited by 735
Emerging insights into the molecular and cellular basis of glioblastoma
Dunn, G. P., Rinne, M. L., Wykosky, J., Genovese, G., Quayle, S. N., Dunn, I. F., Agarwalla, P. K., Chheda, M. G., Campos, B., Wang, A., et al. (2012) · Genes & Development · doi:10.1101/gad.187922.112 · Cited by 565
Inda, M.-D.-M., Bonavia, R., Mukasa, A., Narita, Y., Sah, D. W. Y., Vandenberg, S., Brennan, C., Johns, T. G., Bachoo, R., Hadwiger, P., et al. (2010) · Genes & Development · doi:10.1101/gad.1890510 · Cited by 543
Metadata
- Authors
- Jaros, E., Perry, R., Adam, L., Kelly, P., Crawford, P., Kalbag, R., Mendelow, A., Sengupta, R., & Pearson, A.
- Venue
- British Journal of Cancer
- Published
- 1992-08
- Volume
- 66
- Issue
- 2
- Pages
- 373-385
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1969363807
- Cited by
- 264
- References
- 43
- FWCI
- 10.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.